Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

Contributed by: PR Newswire

Tags

LUNDBECK-Amlenetug

More Like This

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Exidavnemab phase 2a study expanded to include MSA patients

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy